Michael Gillespie is listed as a director on 1 SEC Form D filing by 1 issuer in Jun 2023: Pluton Biosciences, Inc. (St. Louis, MO — biotechnology — 2023; $17.6M reported sold to 38 investors).
What this means One deal on file with the SEC, filed Jun 2023. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Barry Goldman (1 shared filing), Charles Lin (1 shared filing), Clay Mitchell (1 shared filing), Elizabeth Gallegos (1 shared filing), Gerald Steiner (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for Michael Gillespie and found 4 differences, 1 worth asking the sponsor about: Form D filed 98 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.